Long Position on INSY @ $41.50 on 12/15/2014 (Momentum)

Insys Therapeutics, Inc. (INSY) is  a commercial-stage specialty pharmaceutical company.

The firm develops and commercializes supportive care products.

It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients; and Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol.

It offers its Subsys through its incentive-based commercial sales force.

The company also provides Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. 

Shares have formed a bullish "wedge" or "pennant" and higher share prices are expected for this stock. The formation is supported by the stock's 50-day moving average. 

52-Week Trading Range: $20.52 - $57.91

Entry Point: $41.50

Stop Loss: $39.42

Target Price: $45.65

Updates

12/18/2014 10:44:15 AM

INSY reached our target. Closed at $45.70.

Position closed on 12/18/2014 at price of $45.70 with a 10.12% gain in 3 days.

Back to Portfolio